ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
Trial Parameters
Brief Summary
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).
Eligibility Criteria
Inclusion Criteria: * age ≥18 years; * left ventricular ejection fraction (LVEF) \<50%; * Presence of functional mitral regurgitation (mild, moderate, or severe) on transthoracic echocardiography; and * stable sinus rhythm or controlled atrial fibrillation. Exclusion Criteria: * primary (degenerative or rheumatic) mitral valve disease, * prior mitral valve surgery or transcatheter intervention, * acute decompensated heart failure within four weeks, * significant primary valvular disease other than FMR, * severe renal impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m²), * inadequate echocardiographic image quality.